Correction of muscular dystrophies by CRISPR gene editing

Francesco Chemello, Rhonda Bassel-Duby, Eric N. Olson

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


Muscular dystrophies are debilitating disorders that result in progressive weakness and degeneration of skeletal muscle. Although the genetic mutations and clinical abnormalities of a variety of neuromuscular diseases are well known, no curative therapies have been developed to date. The advent of genome editing technology provides new opportunities to correct the underlying mutations responsible for many monogenic neuromuscular diseases. For example, Duchenne muscular dystrophy, which is caused by mutations in the dystrophin gene, has been successfully corrected in mice, dogs, and human cells through CRISPR/Cas9 editing. In this Review, we focus on the potential for, and challenges of, correcting muscular dystrophies by editing disease-causing mutations at the genomic level. Ideally, because muscle tissues are extremely long-lived, CRISPR technology could offer a one-time treatment for muscular dystrophies by correcting the culprit genomic mutations and enabling normal expression of the repaired gene.

Original languageEnglish (US)
Pages (from-to)2766-2776
Number of pages11
JournalJournal of Clinical Investigation
Issue number6
StatePublished - Jun 1 2020

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Correction of muscular dystrophies by CRISPR gene editing'. Together they form a unique fingerprint.

Cite this